The role of CA-125, GLS and FASN in predicting cytoreduction for epithelial ovarian cancers

Abstract

Objective: Cytoreduction has an important role in improving the survival rate of epithelial ovarian cancer (EOC) patients. This study aimed to assess the ability of preoperative serum CA125, FASN and GLS as predictors of cytoreductive surgery for epithelial ovarian cancer (EOC). Results: The average values of serum CA-125, FASN, and GLS in the suboptimal cytoreduction group were higher than those in optimal cytoreduction group. The cut off point (COP) was 248.55 (p = 0.0001) with 73.2% sensitivity and 73.6% specificity for CA-125, 0.445 (p = 0.017) with 62.5% sensitivity and 60.4% specificity for FASN, and 22.895 (p = 0.0001) with 73.2% sensitivity and 75.5% specificity for GLS. The COP of CA-125 and GLS combined was 29.16 (p = 0.0001) with sensitivity 82.1% and specificity 73.6%, while the COP of CA-125, GLS, and FASN combined was 0.83 (p = 0.0001) with 87.5% sensitivity and 73.6% specificity.

CA125-Associated Activated Partial Thromboplastin Time and Thrombin Time Decrease in Patients with Adenomyosis [Letter]

“…It is hoped that this combination can help doctors provide better therapy. 4 In conclusion, we agree that the shortening of APTT and TT related to CA125 shows the importance of early detection of coagulation parameters in patients with elevated CA125 levels to determine hypercoagulability and prevent thrombi in adenomyosis. 1 However, several studies have found that CA-125 is not a strong enough predictor if stands alone in diagnostic screening, but it requires a combination of several biomarkers which also play a role in predicting and preventing thrombosis, therefore it is necessary to carry out further research with larger samples so that the results of this research will continue to develop.…”

Comparison of glutaminase and cancer antigen 125 for distinguishing benign and malignant ovarian tumors

“…Furthermore, another study that specifically investigated the role of GLS in predicting optimal cytoreductive surgery in patients with EOC identified a cutoff point of 22.895. 15 Tumor growth is accompanied by distinct metabolic changes. The increased proliferation of tumor cells requires an alteration in metabolic functions to support their division.…”

“…This cutoff point was determined to be 18.32. Furthermore, another study that specifically investigated the role of GLS in predicting optimal cytoreductive surgery in patients with EOC identified a cutoff point of 22.895 15 …”